BridgeBio Pharma, Inc. (BBIO) Total liabilities 2019–2025
BridgeBio Pharma, Inc. (BBIO) total liabilities at each fiscal year-end, per SEC filings.
$3.0BFY2025 · since FY2019: $155.7M → $3.0B
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $3.0B | +26.7% |
| FY2024 | $2.4B | +25.8% |
| FY2023 | $1.9B | +1.1% |
| FY2022 | $1.9B | -0.6% |
| FY2021 | $1.9B | +215.3% |
| FY2020 | $595.7M | +282.6% |
| FY2019 | $155.7M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice